STAT+: Pharmalittle: We’re reading about drug shortages, Medicare spending on an Alzheimer’s drug, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, despite…
Category: Pharma
STAT+: European Parliament votes in favor of updated pharma legislation, prompting mixed reactions
The European Parliament has voted overwhelmingly to adopt legislation that is supposed to transform the…
STAT+: Drug shortages reached a record high as 2023 drew to a close
The number of ongoing and active drug shortages in the U.S. stood at 323 during…
STAT+: Regeneron accused by Justice Department of manipulating Medicare pricing
The U.S. Department of Justice filed a lawsuit accusing Regeneron Pharmaceuticals of manipulating Medicare pricing…
STAT+: Pharmalittle: We’re reading about a 486% drug price hike, AstraZeneca CEO pay, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
AskBio CSO steps down, has new project in stealth mode
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Did you say 486%? Why one company thinks such a price hike for its drug is justified
In an era when huge price hikes for prescription drugs are almost guaranteed to draw…
STAT+: Virginia governor vetoes plans to create a prescription drug affordability board
Virginia Gov. Glenn Youngkin vetoed a bill that would have created a new entity for…
STAT+: Biden administration urged to license prostate cancer drug patents in a bid to lower its cost
In the latest gambit to lower the cost of a pricey medicine, three advocacy groups…
STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
Pfizer’s plot to win the RSV vaccine race
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The latest updates on cancer research from the weekend
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: FDA agrees to review a rare disease drug that its developer was about to give up on
File this under “Not a moment too soon.” After years of back-and-forth deliberations, the U.S….
STAT+: Positive trial results set up obesity drug Wegovy for use against heart failure
ATLANTA — Novo Nordisk’s Wegovy improved symptoms and physical function in patients who had obesity,…
STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more
And so, another working week will soon draw to a close. Not a moment too…
Sanofi resolves most Zantac litigation
Want to stay on top of the science and politics driving biotech today? Sign up to get…
How resurrecting extinct species might impact medicine
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Amylyx pulling its ALS drug, GLP-1 drugs for Parkinson’s, and more
Top of the morning to you, and a fine one it is. After two days…
New data on liquid biopsy for colorectal cancer detection still underwhelms
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a White House drug-shortage plan, a Genmab deal, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
Lawmakers want to add more Chinese biotechs to defense list
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: The biotech scoreboard for the second quarter: 32 stock-moving events to watch
Here is STAT’s biotech scoreboard, our regular ledger of stock-moving biotech events, for the second…
STAT+: Net prices for medicines fell considerably in 2023’s last quarter, mostly thanks to Humira biosimilars
The net prices that health plans paid for medicines — after subtracting rebates, discounts, and…
Aardvark Therapeutics gearing up for $200 million IPO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about AstraZeneca’s CEO pay, an ALS drug spat in the U.K., and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
GLP-1 generics would be dramatically cheaper than U.S. price of Ozempic, study shows, but still profitable
Diabetes drugs are too expensive in the U.S., and insulin is infamously six to 13…
STAT+: Pharmalittle: We’re reading about Wegovy insurance coverage, Zepbound shortages, and more
And so, another working week will soon draw to a close. Not a moment too…
What’s Congress going to do with WuXi?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Payments by drug and device makers to doctors remain widespread, but also vary considerably
The financial ties between drug and device makers and some physicians remains pervasive, despite concerns…
STAT+: Pharmalittle: We’re reading about a GLP-1 side effect, U.K. clinical trial transparency, and more
Top of the morning to you and a fine one it is. Despite cloudy skies…
STAT+: U.K. becomes the first country to release detailed data on sponsors that fail to register clinical trials
The United Kingdom has released comprehensive data showing which institutions have failed to register their…
How GLP-1’s moved from research labs to national TV
Today is the inaugural publishing day for Adam’s Biotech Scorecard — a subscriber-only newsletter offering…
Brazil’s plan for low-cost CAR-Ts
New biotech newsletter launching tomorrow. Don’t miss out. Good morning, everyone. Damian here with the…
STAT+: Pharmalittle: We’re reading about abortion pill arguments, a Merck drug approval, and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this…
STAT+: AstraZeneca sues Arkansas over the role of pharmacies in a federal discount drug program
AstraZeneca filed a lawsuit seeking to block an Arkansas law that requires the company to…
STAT+: FDA is still struggling to inspect clinical research sites, watchdog finds
The U.S. Food and Drug Administration’s oversight of clinical research in hospitals and clinics has…
STAT+: Roche subsidiary Foundation Medicine opens new headquarters in Boston
Contemporary paintings by artists who have overcome homelessness or disabilities greet visitors in the lobby….
STAT+: European antitrust regulators probe Zoetis over pain drug for dogs
The European Commission has opened a formal antitrust investigation to determine whether Zoetis, one of…
STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more
Rise and shine, everyone, another busy day is on the way. How so? The evidence…
Merck’s next big thing is (probably) on the way
New biotech newsletter launching this Thursday. Don’t miss out. Hello, everyone. Damian here with a look…
STAT+: Amgen sues Colorado over its prescription drug affordability board
Amgen has filed a lawsuit accusing a Colorado state board of violating the U.S. Constitution…
STAT+: Merck drug for rare, deadly lung condition appears set for approval in U.S.
The Food and Drug Administration is expected to approve Merck’s drug to treat a rare…
STAT+: Chick-fil-A drops a ‘No Antibiotic Ever’ pledge on chicken over supply issues
Chick-fil-A, one of the largest fast-food restaurants in the U.S., is easing its commitment to…
STAT+: Vertex Pharmaceuticals is considering relocating its headquarters
When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that…
How will the Supreme Court’s mifepristone decision impact biopharma?
New biotech newsletter launching this Thursday. Don’t miss out. Hey there. Today, we discuss the…
STAT+: Pharmalittle: We’re reading about a Novo Nordisk deal, a Regeneron setback, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Novo Nordisk to acquire heart-disease focused Cardior Pharmaceuticals in deal worth $1.1 billion
LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in…
SCOTUS’ abortion pill mifepristone case is really about the FDA
WASHINGTON — The Supreme Court on Tuesday will hear opening arguments in an abortion medication…